Detalles de la búsqueda
1.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
J Infect Dis
; 215(1): 95-104, 2017 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28077588
2.
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
J Infect Dis
; 213(6): 1013-7, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26563240
3.
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
J Antimicrob Chemother
; 71(4): 1031-6, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26679246
4.
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Antimicrob Agents Chemother
; 59(10): 6080-6, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26195515
5.
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60âyears of age.
HIV Clin Trials
; 16(1): 39-42, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25777188
6.
Pharmacology lessons from chemoprophylaxis studies.
Clin Infect Dis
; 59 Suppl 1: S52-4, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24926035
7.
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
J Antimicrob Chemother
; 69(7): 1911-5, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24610312
8.
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Front Immunol
; 15: 1400553, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38817615
9.
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Antimicrob Agents Chemother
; 57(8): 3640-4, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23689708
10.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
Antimicrob Agents Chemother
; 56(3): 1427-33, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22183172
11.
CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.
Mol Med
; 18: 1240-8, 2012 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-22875102
12.
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Antimicrob Agents Chemother
; 55(9): 4218-23, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21709075
13.
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
J Antimicrob Chemother
; 66(4): 885-9, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21393207
14.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
J Antimicrob Chemother
; 66(3): 635-40, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21172791
15.
Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Br J Nutr
; 102(7): 1038-46, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19480729
16.
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
HIV Clin Trials
; 19(1): 31-37, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29189101
17.
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS
; 21(11): 1449-55, 2007 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-17589191
18.
An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
Antivir Ther
; 22(2): 145-151, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-27708251
19.
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
J Acquir Immune Defic Syndr
; 73(3): 252-257, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27727157
20.
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors.
AIDS Rev
; 6(4): 208-17, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15700619